Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2012 07:00 ET | Source: Gentium S.p.A.

Gentium To Initiate Clinical Development in Japan and Expand Named-Patient Program Access to Asia and Japan

VILLA GUARDIA (COMO), Italy, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced the Company's entry into an agreement with the National University...
November 15, 2012 07:00 ET | Source: Gentium S.p.A.

Gentium Reports Third Quarter 2012 Financial Results

Defibrotide usage increased 39% to EUR 17.14 million (USD 22.16 million) for the nine-month period ended September 30, 2012 from EUR 12.33 million during the prior-year period. Product sales...
October 10, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Receives Second List of Outstanding Issues From the EMA's CHMP for Defibrotide MAA

VILLA GUARDIA, Italy, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it has received a second List of Outstanding Issues ("LoOIs") from the...
October 04, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Appoints Biologix FZCo as Exclusive Distributor of Defibrotide in the Middle East and North Africa

VILLA GUARDIA (COMO), Italy, Oct. 4, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced today the appointment of Biologix FZCo as the exclusive distributor of Defibrotide in the Middle...
September 26, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Provides Update on the Review of Defibrotide Marketing Authorization Application

VILLA GUARDIA, Italy, Sept. 26, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that, following the Company's presentation of Oral Explanations to the European...
September 13, 2012 07:00 ET | Source: Gentium S.p.A.

Gentium Reports First Half 2012 Financial Results

Defibrotide usage increased 38% to EUR 11.35 million (USD 14.29 million) for the six-month period ended June 30, 2012 from EUR 8.23 million in the prior-year period Product sales of EUR 13.68...
September 11, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium to Present Oral Explanations to EMA's CHMP for Defibrotide MAA

VILLA GUARDIA, Italy, Sept. 11, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been asked to present Oral Explanations on September 19, 2012 to the...
September 10, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium to Review First Half 2012 Financial Results

VILLA GUARDIA (COMO), Italy, Sept. 10, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it will hold a conference call and live webcast with management to...
June 21, 2012 07:30 ET | Source: Gentium S.p.A.

Gentium Submits Day 180 Response to List of Outstanding Issues Received From the EMA's CHMP for Defibrotide MAA

VILLA GUARDIA, Italy, June 21, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has submitted its responses to the Day 180 List of Outstanding Issues (the...
May 17, 2012 08:56 ET | Source: Gentium S.p.A.

Gentium Reports First Quarter Financial Results

Defibrotide usage increased by 28% to EUR 4.93 million (US $6.56 million). Product sales of EUR 5.65 million (US $7.51 million) for the three month period ended March 31, 2012, recording an...